Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxazepam
Drug ID BADD_D01636
Description Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism.[A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions.[L13895]
Indications and Usage For the treatment of anxiety disorders and alcohol withdrawal.
Marketing Status Prescription; Discontinued
ATC Code N05BA04
DrugBank ID DB00842
KEGG ID D00464
MeSH ID D010076
PubChem ID 4616
TTD Drug ID D09LDR
NDC Product Code 62584-812; 43353-965; 62584-813; 0228-2067; 72166-009; 64330-015; 0228-2069; 67544-117; 71610-639; 0228-2073; 43353-980; 48087-0087; 62584-814; 12828-0024; 52817-292; 52817-290; 52817-291; 67544-268
Synonyms Oxazepam | Serax | Tazepam | Adumbran
Chemical Information
Molecular Formula C15H11ClN2O2
CAS Registry Number 604-75-1
SMILES C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rhabdomyolysis15.05.05.0020.013932%
Sedation17.02.04.0050.006966%Not Available
Seizure17.12.03.0010.006966%
Shock24.06.02.002--Not Available
Sinus tachycardia02.03.03.0100.010449%
Somnolence19.02.05.003; 17.02.04.0060.024380%
Status epilepticus17.12.03.0050.006966%Not Available
Stupor17.02.04.007; 19.02.05.004--Not Available
Suicidal ideation19.12.01.0030.010449%
Suicide attempt19.12.01.0040.005452%
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tachycardia02.03.02.0070.010449%Not Available
Tremor17.01.06.0020.020897%
Urinary retention20.02.02.0110.006966%
Urticaria10.01.06.001; 23.04.02.001--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.0030.017415%
Weight increased13.15.01.0060.006966%
Withdrawal syndrome08.06.02.012; 19.07.02.0050.006966%Not Available
Paradoxical drug reaction08.06.01.014--Not Available
Deep vein thrombosis24.01.02.0030.001817%Not Available
Foetal death18.01.02.003; 08.04.01.0110.001817%
Libido disorder21.03.02.006; 19.08.03.004--Not Available
Mental disorder19.07.01.0020.006966%Not Available
Psychiatric symptom19.01.02.0010.006966%Not Available
Blood disorder01.05.01.004--Not Available
Psychiatric decompensation19.01.02.0100.006966%Not Available
Acute kidney injury20.01.03.0160.006966%
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.001817%Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages